Alzheimers Disease Diagnostic Market

  • Published on 2025-11-04
  • Report Code: 1668
  • 170-350 pages
Alzheimers Disease Diagnostic Market

Alzheimers Disease Diagnostic Market Size, Share, and Analysis, By Type (Early Onset Alzheimers, Late Onset Alzheimers, Familial Alzheimers Disease, Others), By Diagnostic Test (PET, SPECT, Blood based ELISA Test, CSF Assays, Others), By End User (Clinic, Hospital, Diagnostic Center, Others) and Regional Forecasts, 2022-2032

Table Of Content

1. Executive Summary 

1.1. Regional Market Share

1.2.  Business Trends

1.3.  Alzheimer's Disease Diagnostic  Market:  COVID-19 Outbreak

1.4. Regional Trends

1.5.  Segmentation Snapshot

2. Research Methodology 

2.1.  Research Objective

2.2. Research Approach

2.3. Data Sourcing and Methodology 

2.4.  Primary Research

2.5.  Secondary Research

2.5.1. Paid Sources

2.5.2.  Public Sources

2.6.Market Size Estimation and Data Triangulation

3. Market Characteristics 

3.1. Market Definition

3.2.Alzheimers Disease Diagnostic Market: COVID-19 Impact

3.3.Key Segmentations 

3.4. Key Developments

3.5. Allied Industry Data

4. Alzheimers Disease Diagnostic Market – Industry Insights

4.1.Industry Segmentation

4.2. COVID-19 overview on world economy

4.3. Industry ecosystem Channel analysis

4.4. Innovation & Sustainability

5. Macroeconomic Indicators

6. Recent Developments

7.Market Dynamics

7.1. Introduction

7.2.Growth Drivers

7.3.Market Opportunities

7.4. Market Restraints

7.5.Market Trends

8. Market Analysis

8.1. Porters Five Forces

8.2. PEST Analysis

8.2.1. Political 

8.2.2.Economic

8.2.3.Social

8.2.4.Technological

9. Alzheimers Disease Diagnostic Market

9.1. Overview

9.2.Historical Analysis (2016-2021)

9.2.1. Market Size, Y-o-Y Growth (%) and Market Forecast

10. Alzheimers Disease Diagnostic Market Size & Forecast 2022A-2032F 

10.1.Overview

10.2. Key Findings

10.3. Market Segmentation

10.3.1. By Type

10.3.1.1.Early Onset Alzheimers

10.3.1.1.1.By Value (USD Million) 2022-2032F

10.3.1.1.2. Market Share (%) 2022-2032F

10.3.1.1.3. Y-o-Y Growth (%) 2022-2032F

10.3.1.2. Late Onset Alzheimers

10.3.1.2.1. By Value (USD Million) 2022-2032F

10.3.1.2.2.Market Share (%) 2022-2032F

10.3.1.2.3.Y-o-Y Growth (%) 2022-2032F

10.3.1.3. Familial Alzheimers Disease

10.3.1.3.1. By Value (USD Million) 2022-2032F

10.3.1.3.2.Market Share (%) 2022-2032F

10.3.1.3.3.Y-o-Y Growth (%) 2022-2032F

10.3.1.4. Others

10.3.1.4.1.By Value (USD Million) 2022-2032F

10.3.1.4.2. Market Share (%) 2022-2032F

10.3.1.4.3. Y-o-Y Growth (%) 2022-2032F

10.3.2.By Diagnostic Test

10.3.2.1. PET

10.3.2.1.1. By Value (USD Million) 2022-2032F

10.3.2.1.2.Market Share (%) 2022-2032F

10.3.2.1.3.Y-o-Y Growth (%) 2022-2032F

10.3.2.2.SPECT

10.3.2.2.1.By Value (USD Million) 2022-2032F

10.3.2.2.2. Market Share (%) 2022-2032F

10.3.2.2.3. Y-o-Y Growth (%) 2022-2032F

10.3.2.3.Blood based ELISA Test

10.3.2.3.1.By Value (USD Million) 2022-2032F

10.3.2.3.2. Market Share (%) 2022-2032F

10.3.2.3.3.Y-o-Y Growth (%) 2022-2032F

10.3.2.4.CSF Assays

10.3.2.4.1. By Value (USD Million) 2022-2032F

10.3.2.4.2.Market Share (%) 2022-2032F

10.3.2.4.3.Y-o-Y Growth (%) 2022-2032F

10.3.2.5.Others

10.3.2.5.1.By Value (USD Million) 2022-2032F

10.3.2.5.2.Market Share (%) 2022-2032F

10.3.2.5.3.Y-o-Y Growth (%) 2022-2032F

10.3.3.By End User

10.3.3.1. Clinic

10.3.3.1.1. By Value (USD Million) 2022-2032F

10.3.3.1.2.Market Share (%) 2022-2032F

10.3.3.1.3.Y-o-Y Growth (%) 2022-2032F

10.3.3.2.Hospital

10.3.3.2.1.By Value (USD Million) 2022-2032F

10.3.3.2.2. Market Share (%) 2022-2032F

10.3.3.2.3.Y-o-Y Growth (%) 2022-2032F

10.3.3.3.Diagnostic Center

10.3.3.3.1.By Value (USD Million) 2022-2032F

10.3.3.3.2.Market Share (%) 2022-2032F

10.3.3.3.3.Y-o-Y Growth (%) 2022-2032F

10.3.3.4.Others

10.3.3.4.1. By Value (USD Million) 2022-2032F

10.3.3.4.2.Market Share (%) 2022-2032F

10.3.3.4.3.Y-o-Y Growth (%) 2022-2032F

11.North America Alzheimers Disease Diagnostic Market Size & Forecast 2022A-2032F

11.1.Overview

11.2. Key Findings

11.3. Market Segmentation

11.3.1.By Type

11.3.2. By Diagnostic Test

11.3.3. By End User

11.4.Country

11.4.1. United States

11.4.2.Canada

12. Europe Alzheimers Disease Diagnostic Market Size & Forecast 2022A-2032F

12.1. Overview

12.2. Key Findings

12.3. Market Segmentation

12.3.1. By Type

12.3.2.By Diagnostic Test

12.3.3.By End User

12.4. Country

12.4.1.Germany

12.4.2. United Kingdom

12.4.3. France

12.4.4. Italy

12.4.5. Spain

12.4.6. Russia

12.4.7. Rest of Europe (BENELUX, NORDIC, Hungary, Turkey & Poland)

13. Asia Alzheimers Disease Diagnostic Market Size & Forecast 2022A-2032F

13.1. Overview

13.2. Key Findings

13.3. Market Segmentation

13.3.1. By Type

13.3.2.By Diagnostic Test

13.3.3. By End User

13.4.  Country

13.4.1. India

13.4.2.  China

13.4.3.  South Korea

13.4.4.  Japan

13.4.5.  Rest of APAC

14. Middle East and Africa Alzheimer's Disease Diagnostic Market Size & Forecast 2022A-2032F 

14.1. Overview

14.2.  Key Findings

14.3.  Market Segmentation

14.3.1.  By Type

14.3.2. By Diagnostic Test

14.3.3. By End User

14.4.  Country

14.4.1. Israel

14.4.2.  GCC

14.4.3.  North Africa

14.4.4.  South Africa

14.4.5.  Rest of Middle East and Africa

15. Latin America Alzheimers Disease Diagnostic Market Size & Forecast 2022A-2032F 

15.1. Overview

15.2.  Key Findings

15.3.  Market Segmentation

15.3.1.  By Type

15.3.2. By Diagnostic Test

15.3.3. By End User

15.4.  Country

15.4.1. Mexico

15.4.2.  Brazil

15.4.3.  Rest of Latin America

16. Competitive Landscape 

16.1.  Company market share, 2021

16.2.  Key player overview

16.3.  Key stakeholders

17. Company Profiles  

17.1. Johnson & Johnson

17.1.1. Company Overview

17.1.2.  Financial Overview

17.1.3.  Key Product; Analysis

17.1.4. Company Assessment

17.1.4.1. Product Portfolio

17.1.4.2.  Key Clients

17.1.4.3.  Market Share 

17.1.4.4.  Recent News & Development (Last 3 Yrs.)

17.1.4.5.  Executive Team

17.2. Novartis AG 

17.3. F. Hoffmann-La Roche Ltd 

17.4. Pfizer Inc. 

17.5. Merck & Co. 

17.6. GE Healthcare 

17.7. AbbVie 

17.8. Eli Lilly and Company 

17.9. Daiichi Sankyo 

17.10. Sysmex 

17.11. Quanterix

17.12. Alector LLC 

17.13. Corium Inc 

17.14. TauRx Therapeutics 

17.15. Cognition Therapeutics Inc 

17.16. Other Prominent Players 

18. Appendix 

19. Consultant Recommendation 

To request a free sample copy of this report, please complete the form below.

Select License Type

$ 4950

Report accessible by 1 user only

In case you require a hard copy, there will be an additional charge of $500. Please email us at [email protected] with your request.

Read all reports

Our Clients

We have been working with some Fortune 500+ clients